Emirates News Agency – Ministry of Health – Abu Dhabi adopts ‘population health model’
ABU DHABI, November 10, 2021 (WAM) – The Abu Dhabi Ministry of Health (DoH) has become the first healthcare regulatory body in the region and the second in the world to adopt and develop the ‘Model of population health â(PHM).
The model, which will aid in the early detection, management and comprehensive prevention of cardiovascular disease (CVD), was developed in cooperation with the Swiss multinational pharmaceutical company Novartis. This was part of the department’s ongoing efforts to strengthen the emirate’s stature as a global healthcare destination and incubator for innovation.
The PHM will also help adopt preventive measures against CVD and reduce the number of CVD cases and complications among residents of the emirate by providing data that will enable healthcare professionals to provide recommendations and programs for prevention needed by patients.
The model involves the application of public health concepts to manage chronic disease through a holistic data analysis approach and identifies methods and interventions to improve patient outcomes while controlling overall costs. The information gathered can also help identify and fill gaps in patient care.
A Memorandum of Understanding between the DoH and Novartis was signed by Dr Jamal Mohammed Al Kaabi, Undersecretary of the DoH, and Mohamed Ezz Eldin, Chairman and Head of the Gulf Cluster of Novartis, in the presence of Abdulla bin Mohamed Al Hamed , Chairman of the DoH, and Georg Schroeckenfuchs, Chairman MEA and Head of the Gulf and Saudi Country Group at Novartis.
Their collaboration aims to invest in research, education, digital and organizational infrastructure to fight cardiovascular disease and develop the emirate’s MPS program. It also aims to use the latest innovations, life sciences and technologies from the local health sector to ensure the health and safety of the community.
Abdulla bin Mohamed Al Hamed, President of DoH, said: âWith the guidance of our leadership and guidance, we continue to build strong and fruitful collaborations with partners around the world, to strengthen the effectiveness of the health system. and maintain the health and safety of our community. The DoH will continue to embrace advanced innovations and partner with relevant entities to help us achieve our goal of positioning the emirate as a global healthcare hub while improving the future of the healthcare system. .
Cardiovascular disease is a group of disorders of the heart and blood vessels, and includes coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other conditions. More than four in five CVD deaths are due to heart attacks and strokes, and a third occur prematurely in people under the age of 70.
âCardiovascular disease is a major cause of death, hospitalization and poor quality of life in patients. Therefore, it has become a key priority for UAE health institutes, especially the DoH, to research new approaches to bend the curve of cardiovascular events. The PHM is a healthcare ecosystem alliance that offers a holistic approach to transforming the management of CVD patients in the UAE, âsaid Ezz Eldin.
âThe DoH is on its way to becoming the second international healthcare system after the NHS to explore the population approach, reinforcing its vision of fostering innovation in the region. We are proud of this initiative, which is part of a comprehensive mutual cooperation to add greater value for patients in Abu Dhabi, âhe added.
Cardiovascular disease is the leading cause of death worldwide, with an estimated death rate of 17.9 million in 2019.
As a leading global pharmaceutical company, Novartis uses innovative scientific and digital technologies to develop transformative treatments in areas of urgent medical need. Her products have reached nearly 800 million people worldwide and she is finding innovative ways to expand access to her latest treatments. Some 109,000 employees of over 140 nationalities work in Novartis offices around the world.